Page 20 - FIMM_Brochure_2022
P. 20
CaWnoodrrelSdFt-acatlceai-lsoistfi-Ietnhsfer-aAstrrtucture
The FIMM Technology Centre FIMM operates world-class infrastructure enabling outstanding
science and early introduction of technologies into translation-
FIGKUERYES al research and clinical testing operations.
4.7M€ FIMM Technology Centre (TC) provides professional research services for local,
national and international research communities. All of our services are open access
total revenue in 2021 and available to academic and commercial users on a ‘first come-first served’ basis.
We improve our services continually by developing novel methods in collaboration
Supports with research groups, renewing key instrumentation, and setting up new technolo-
gies in response to the needs of research communities.
>500
As of August 2022, the FIMM TC hosts 10 core facilities run by technology experts.
research groups per year Most of the facilities are members of local (HiLIFE) and national (Biocenter Finland)
technology platforms. Additionally, FIMM TC staff are active in several European
55,000 Strategy Forum on Research Infrastructures (ESFRIs). FIMM TC core facilities are
evaluated regularly as part of their larger platforms, and individual facilities have
samples handled by been successful in international benchmarking activities including those organised
the Genomics unit in 2021 by EATRIS and other ESFRIs, the Nordic Alliance in Clinical Genomics (NACG) and the
European 1+ Million Genomes Initiative.
50,818
The FIMM TC Genomics Unit was instrumental in Finland’s COVID-19 pandemic re-
COVID-19 virus sponse by performing national SARS-CoV-2 sequencing and providing free-of-charge
samples sequenced genome-wide association studies (GWAS) genotyping for low-resource countries as
part of the international COVID-19 Host Genetics Initiative led by FIMM researchers
(as of June 2022) (p. 14).
Furthermore, and as examples of recent technology transfer, the FIMM TC Genomics
Unit founded a joint genome unit (HUSGEN) with the Helsinki University Hospital
(HUS) with a focus on clinical sequencing, and has trained the Finnish Institute for
Health and Welfare (THL), Finland’s national public health authority, on next genera-
tion sequencing technology for application on SARS-CoV-2 sequencing.
Additional notable, recent developments in the FIMM TC include:
l Sample processing and data generation for iCAN, an Academy of Finland flagship project
in cancer precision medicine (p. 9)
l Formation of a new Single Cell Competence Centre, a collaboration of the Single Cell
Analytics, High Throughput Biomedicine, and High Content Imaging & Analysis units
l Launch of a new high-throughput sample preparation core facility HiPrep
l Completion of two major clinical studies (eCare4Me and VenEx) by the High Throughput
Biomedicine unit, in collaboration with HUS
20 | FIMM – Building a Bridge from Discovery to Medicine
